Glenn Rice

Glenn Rice, Ph.D. has been involved with the start up and building of seven biotech companies as founder/ member of the early executive management team, which has led to significant shareholder returns via two reverse IPO’s, two acquisitions and one IPO. Before serving as Director and President of MetronomX, Dr. Rice was COO, President and Director of Pharmacyclics, Inc. a NASDAQ listed drug company with four drugs in the clinic for cancer, autoimmune and allergic diseases. During his tenure he raised $30M in public equity and the stock price increased 500%. Dr. Rice continues to sit on the Board of Directors for Pharmacyclics. He is founder and former CEO of two China-focused companies, Pacific Biopharma Group, Ltd. (Taizhou), and Bridge Laboratories, Ltd. (Beijing), which he built to 300 employees and significant revenues. Dr. Rice was the former head of life sciences at SRI International directing over 160 staff, and was the former VP of Research and Board Director of NASDAQ listed ILEX Oncology, which was later sold to Genzyme Corp. in 2004 for $1 billion. Prior to ILEX he was a founder and CEO of Convergence Pharmaceuticals, Inc., a Boston-based oncology company; a founder and Director of EmergingMed, an online clinical trial prequalification company; and a past Director and co-founder of C-PATH Institute, a non-profit Institute that is focused on drug development and regulatory innovation. Dr. Rice began his career as a laboratory director at Genentech, and is an inventor on over 20 patents or patent applications, authored over 75 manuscripts and book chapters, and has had extensive experience raising substantial private and public equity and corporate partnerships.